🫁 Experimental Drug Cuts Lung Cancer Death Risk by Half
BioNTech and OncoC4 announced that their experimental drug gotistobart cut the risk of death by 54% versus standard chemotherapy in patients with previously treated squamous non-small cell lung cancer.
The finding, if confirmed in the pivotal stage, could represent a significant new option for a patient group with very limited treatments.
Read More
Post #759
138K
- ❤ 185
- 👍 50
- 🔥 16
- 🌭 10
- 🫡 9
- 🤷♀ 8
- 🤔 8
- 🍾 7
- 🍓 6
- 😁 5
- 🗿 5